Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Dechra Pharmaceuticals PLC
  6. Summary
    DPH   GB0009633180

DECHRA PHARMACEUTICALS PLC

(DPH)
  Report
Delayed London Stock Exchange  -  11:35:04 2023-02-03 am EST
3114.00 GBX   +1.63%
01/12Dechra half-revenue up; outlook for full-year remains "positive"
AN
01/12UBS cuts Beazley; Berenberg likes Rio and BHP
AN
01/12Dechra Pharmaceuticals Retains Positive Outlook For FY23 With 5% Revenue Growth In Fiscal H1
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
2874(c) 2866(c) 2904(c) 3064(c) 3114(c) Last
270 796 289 195 345 262 330 707 306 460 Volume
+1.70% -0.28% +1.33% +5.51% +1.63% Change
More quotes
Estimated financial data (e)
Sales 2023 793 M 959 M 959 M
Net income 2023 68,9 M 83,3 M 83,3 M
Net Debt 2023 351 M 425 M 425 M
P/E ratio 2023 55,3x
Yield 2023 1,50%
Sales 2024 855 M 1 034 M 1 034 M
Net income 2024 91,4 M 111 M 111 M
Net Debt 2024 268 M 324 M 324 M
P/E ratio 2024 42,2x
Yield 2024 1,63%
Capitalization 3 545 M 4 288 M 4 288 M
EV / Sales 2023 4,91x
EV / Sales 2024 4,46x
Nbr of Employees -
Free-Float 99,1%
More Financials
Company
Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows:... 
Sector
Pharmaceuticals
Calendar
02/27 | 02:00amEarnings Release
More about the company
Ratings of Dechra Pharmaceuticals PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about DECHRA PHARMACEUTICALS PLC
01/12Dechra half-revenue up; outlook for full-year remains "positive"
AN
01/12UBS cuts Beazley; Berenberg likes Rio and BHP
AN
01/12Dechra Pharmaceuticals Retains Positive Outlook For FY23 With 5% Revenue Growth In Fisc..
MT
01/11UK earnings, trading statements calendar - next 7 days
AN
01/11JD Sports and Sainsbury's sparkle during Christmas
AN
01/10UK earnings, trading statements calendar - next 7 days
AN
01/10Jefferies likes Inchcape; HSBC cuts Clarkson
AN
01/09UK earnings, trading statements calendar - next 7 days
AN
01/03Citigroup cuts Wizz Air; Redburn likes CRH
AN
2022Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Co..
CI
2022Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100..
CI
2022Dechra Pharmaceuticals PLC(LSE:DPH) added to FTSE 250 (Ex..
CI
2022Dechra Pharmaceuticals PLC(LSE:DPH) added to FTSE 250 Ind..
CI
2022LONDON MARKET MIDDAY: Stocks slide amid risk-off mood after China d..
AN
2022LONDON MARKET OPEN: Pharmaceutical stocks led by GSK spare FTSE 100
AN
More news
News in other languages on DECHRA PHARMACEUTICALS PLC
01/23Vetoquinol SA : El cuidado de los animales
01/20Vetoquinol SA : Aux petits soins des animaux
01/12Le revenu semestriel de Dechra est en hausse ; les perspectives pour l'année entière re..
01/12UBS réduit Beazley ; Berenberg aime Rio et BHP
01/12Dechra Pharmaceuticals maintient des perspectives positives pour l'exercice 23 avec une..
More news
Analyst Recommendations on DECHRA PHARMACEUTICALS PLC
More recommendations
ETFs positioned on DECHRA PHARMACEUTICALS PLCETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AMUNDI MSCI UK IMI SRI PAB DR - EUR (C)2.1%0.62%-UK
Amundi MSCI UK IMI SRI PAB DR (D) - EUR2.1%0.66%-UK
AMUNDI MSCI UK IMI SRI PAB DR - GBP (C)2.1%1.87%-UK
SPDR S&P UK Dividend Aristocrats - GBP0.92%1.41%UK
Xtrackers MSCI UK ESG 1D - GBP0.45%-0.19%-UK
More ETFs positioned on DECHRA PHARMACEUTICALS PLC
Chart DECHRA PHARMACEUTICALS PLC
Duration : Period :
Dechra Pharmaceuticals PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECHRA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 3 114,00 GBX
Average target price 3 992,91 GBX
Spread / Average Target 28,2%
EPS Revisions
Managers and Directors
Ian David Page Chief Executive Officer & Executive Director
Paul Sandland Chief Financial Officer & Executive Director
Alison Elizabeth Platt Chairman
Patrick Meeus Group Scientific Officer
Ishbel Jean Stewart Macpherson Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
DECHRA PHARMACEUTICALS PLC18.95%4 288
ZOETIS14.50%78 207
ELANCO ANIMAL HEALTH INCORPORATED13.50%6 577
BLUESTAR ADISSEO COMPANY7.38%3 518
VIRBAC27.19%2 660
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.21.86%2 138